GlassScriptPhysician profile
Omayra Silva
NPI 1619502218
$15,939.65
in general payments reported to CMS, 2019-2025
41 companies · $1,472 in 2025
The $1,472 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,079 · 2022: $3,487 · 2023: $3,918 · 2024: $3,985 · 2025: $1,472.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,367 · Education: $7.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,367.10 |
| Education | $7.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,616.18 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,821.09 | 2021-2025 | |
| Lilly USA, LLC | $2,581.85 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $978.20 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Bayer Healthcare Pharmaceuticals INC. | $886.56 | 2021-2024 | |
| Currax Pharmaceuticals LLC | $674.65 | 2021-2025 | Contrave, Onzetra Xsail, Nexletol |
| Corcept Therapeutics | $544.82 | 2021-2024 | Korlym |
| Astrazeneca Pharmaceuticals LP | $501.93 | 2021-2025 | Farxiga, Airsupra |
| Aimmune Therapeutics, INC. | $458.94 | 2024-2025 | Zenpep |
| Dexcom, INC. | $458.84 | 2022-2023 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $381.51 | 2021-2023 | |
| Xeris Pharmaceuticals, INC. | $256.64 | 2024 | Gvoke Hypopen, Recorlev |
| Axsome Therapeutics, INC. | $181.62 | 2024 | Auvelity, Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.63 | 2022-2023 | Trulance, Xifaxan |
| Bausch Health US, LLC | $170.29 | 2021-2025 | Aplenzin, Wellbutrin |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omayra Silva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.